Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyNeuro-OncologyRadiotherapyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaBladder CancerBreast CancerHepatocellular CarcinomaLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMalignant MeningitisPancreatic CancerThyroid CancerTumor, Various OrgansTumor Biomarker DefinedSubgroupALK+BRAF V600E mutationBrain Metastasesc-Met-overexpressingEGFR activating mutationEGFR exon 19 deletion mutationEGFR exon 20 insertionEGFR exon 21 Leu858Arg mutationEGFR T790M mutationEGFR wild typeHER2+HER2-mutatedKRAS G12C-MutationMET AmplificationMETex14 skipping mutationnon-squamousNRG1-FusionPD-L1 >50%PD-L1 from 1%RET fusion positiveROS1+Squamous Cell CarcinomaStage IIIA/Btripel negativeunfitICD10C22.0C24.-C24.0C24.1C24.8C24.9C25.-C34.-C50.-C67.-C73C79.3MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungCarcinoma, Transitional CellCommon Bile Duct NeoplasmsLiver NeoplasmsMeningeal CarcinomatosisPancreatic NeoplasmsSmall Cell Lung CarcinomaThyroid NeoplasmsUrinary Bladder NeoplasmsSequenceALTA-1L: BRGT(90/180), NSCLC, first line, C1 (PID48) -|- BRGT180, C2+ (PID49)ASTRUM-004: SERP4.5/NPAC100/CRBP5, NSCLC (PID3208) -|- SERP4.5, NSCLC, maint. (PID3209)ATEZ1200/BEVA15/PACL175/CRBP5, NSCLC (PID2525) -|- ATEZ1200/BEVA15, maint. (PID1209)Atezo-Brain, GECP17/05: ATEZ1200/PEME500/CRBP5, NSCLC (PID3069) -|- ATEZ1200/PEME500, maint. (PID3070)AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- BEVA 7.5 maint., B (PID187).AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- PEME500/BEVA7.5 maint., B (PID186).BRGT(90/180), NSCLC, second line, C1 (PID54) -|- BRGT180, NSCLC, second line, C2+ (PID55)CALGB 9431: VINO25/CISP80, NSCLC, A (PID261) -|- VINO15/CISP80/Radiation, B (PID262).CETU(400/250)/CISP80/VINO25, NSCLC, C1 (PID190) -|- C2-6 (PID191) -|- Erh (PID192)CheckMate 9LA: NIVO360/IPIL1/NPAC100/CRBP6, NSCLC (PID3166) -|- NIVO360/IPIL1, NSCLC, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PACL200/CRBP6, NSCLC (PID1670) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CISP75, NSCLC (PID1676) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CRBP6, NSCLC (PID1669) -|- NIVO360/IPIL1, maint. (PID1671)CHRYSALISCISP60/ETOP150, NSCLC, neoadj., C1-3 (PID620) -|- CISP50/ETOP100/Radiation, C1 (PID619).CM77T: NIVO360/CISP75/DOCE75, NSCLC, neoadj., C1-4 (PID2645) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PACL175, NSCLC, neoadj., C1-4 (PID2642) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PEME500, NSCLC, neoadj., C1-4 (PID2643) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2644) -|- NIVO480, adj., C5-18 (PID2646)DURV1500/GEMC1250/CISP75, NSCLC, neoadj., C1-4 (PID2493) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/GEMC1250/CRBP5, NSCLC, neoadj., C1-4 (PID2495) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PACL200/CRBP6, NSCLC, neoadj., C1-4 (PID2496) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2492) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CRBP5, NSCLC, neoadj., C1-4 (PID2494) -|- DURV1500, adj., C5-18 (PID2497)EMPOWER-Lung 3: CEMI350/PACL200/CISP75, NSCLC, C1-4 (PID2274) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PACL200/CRBP6, NSCLC, C1-4 (PID2275) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PEME500/CISP75, NSCLC, C1-4 (PID2273) -|- CEMI350/PEME500, C5+ (PID2272).EMPOWER-Lung 3: CEMI350/PEME500/CRBP6, NSCLC, C1-4 (PID2271) -|- CEMI350/PEME500, C5+ (PID2272).ESPATUE: PACL175/CISP50, NSCLC, ind., neoadj., A (PID 852) -|- VINO20/CISP50/Radiation B (PID 853) -|- possibly VINO15/CISP40/Radiation C (PID1169)FLAURA2: OSIM80/PEME500/CISP75, NSCLC, C1-4 (PID2540) -|- OSIM80/PEME500, C5+ (PID2541)FLAURA2: OSIM80/PEME500/CRBP5, NSCLC, C1-4 (PID2543) -|- OSIM80/PEME500, C5+ (PID2541)GEMSTONE-302IMpower130: ATEZ1200/NPAC100/CRBP6, NSCLC (PID1238) -|- ATEZ1200 Erh. (PID1272)IMpower150: ATEZ1200/BEVA15/PACL200/CRBP6, NSCLC (PID1208) -|- ATEZ1200/BEVA15, maint. (PID1209)KEYNOTE-021: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200, maint. (PID1083)KEYNOTE-189: PEMB200/PEME500/CISP75, NSCLC (PID1177) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-189: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-407: PEMB200/NPAC100/CRBP6, NSCLC (PID35) -|- PEMB200, maint. (PID1083)KEYNOTE-407: PEMB200/PACL200/CRBP6, NSCLC (PID36) -|- PEMB200, maint. (PID1083)MARIPOSAMARIPOSA-2: PEME500/CRBP5/AMIV(1600/2240), NSCLC, C1 (PID3198) -|- C2-4 (PID3199) -|- C5+ (PID3200)NADIM II: NIVO360/PACL200/CRBP5, NSCLC, neoadj., C1-3 (PID2387) -|- NIVO480, adj., C4-9 (PID2388)NIVO360/PACL200/CRBP6/BEVA15, NSCLC (PID1929) -|- NIVO360/BEVA15, maint. (PID2126)PACL45/CRBP2/Radiation, NSCLC A (PID253) -|- PACL200/CRBP6 cons., B (PID254)PACL50/CRBP2/Radiation, NSCLC A (PID255) -|- PACL200/CRBP6 cons., B (PID256)PACL200/CRBP6/BEVA15, NSCLC (Adeno) A (PID130) -|- BEVA15 maint., B (PID167)PALOMA-3PAPILLONPARAMOUNT: PEME500/CISP75, NSCLC, A (PID179) -|- PEME500, B, maint. (PID180)PEMB200/CISP75/GEMC1000, NSCLC, neoadj., cycle 1-4 (PID2376) -|- PEMB200, adj., cycle 5-18 (PID2378)PEMB200/PACL90/CRBP5, NSCLC, C1-4 (PID3152) -|- PEMB200, C5+ (PID3153)PEMB200/PEME500/CISP75, NSCLC, neoadj., cycle 1-4 (PID2377) -|- PEMB200, adj., cycle 5-18 (PID2378)PEME50/DEXA5, Malignant Meningitis, C1 (PID2529) -|- C2 (PID2530) -|- C3+ (PID2531)PEME500/CISP75/Radiation, NSCLC, A (PID247) -|- PEME500 cons., B (PID249).PEME500/CRBP5/Radiation, NSCLC (Adeno) A (PID250) -|- PEME500 cons., B (PID251)PEME500/CRBP6, NSCLC (Adeno) A (PID181) -|- PEME500 maint., B (PID182)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (PID183) -|- PEME500/BEVA15 maint., B (PID184)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (Stevenson) (PID188) -|- BEVA15 maint., B (PID189)PERT840/TRAS8/DOCE75, NSCLC, C1 (PID1975) -|- PERT420/TRAS6/DOCE75, NSCLC, C2+ (PID1976)POSEIDON: TREM75/DURV1500/GEMC1250/CISP75, NSCLC, C1-4 (PID2294) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/GEMC1250/CRBP6, NSCLC, C1-4 (PID2293) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/NPAC100/CRBP6, NSCLC, C1-4 (PID2290) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/PEME500/CISP75, NSCLC, C1-4 (PID2296) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)POSEIDON: TREM75/DURV1500/PEME500/CRBP6, NSCLC, C1-4 (PID2295) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)RATIONALE-304: TISL200/PEME500/CISP75, NSCLC (PID2634) -|- TISL200/PEME500, maint. (PID2636)RATIONALE-304: TISL200/PEME500/CRBP5, NSCLC (PID2635) -|- TISL200/PEME500, maint. (PID2636)RATIONALE-307: TISL200/NPAC100/CRBP5, NSCLC (PID2648) -|- TISL200, maint. (PID2649) or TISL400, maint. (PID3066)RATIONALE-307: TISL200/PACL175/CRBP5, NSCLC (PID2647) -|- TISL200, maint. (PID2649) or TISL400, maint. (PID3066)RATIONALE-315: TISL200/PACL175/CISP75, NSCLC, neoadj., C1-3 (PID2919) or TISL200/PACL175/CRBP5, NSCLC, neoadj., C1-3 (PID2920) -|- TISL400, adj., C4-11 (PID2921)RATIONALE-315: TISL200/PEME500/CISP75, NSCLC, neoadj., C1-3 (PID2917) or TISL200/PEME500/CRBP5, NSCLC, neoadj., C1-3 (PID2918) -|- TISL400, adj., C4-11 (PID2921)TRIDENT-1: REPO160, NSCLC, C1 (PID554) -|- REPO160, NSCLC, C2+ (PID555)ChemotherapyChemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBinimetinibBleomycinBrigatinibCabozantinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEncorafenibEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLazertinibLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabRepotrectinibSelpercatinibSerplulimabSotorasibSugemalimabTelisotuzumab VedotinTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineZenocutuzumab Chemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBinimetinibBleomycinBrigatinibCabozantinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEncorafenibEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLazertinibLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabRepotrectinibSelpercatinibSerplulimabSotorasibSugemalimabTelisotuzumab VedotinTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineZenocutuzumab Chemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBinimetinibBleomycinBrigatinibCabozantinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEncorafenibEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLazertinibLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabRepotrectinibSelpercatinibSerplulimabSotorasibSugemalimabTelisotuzumab VedotinTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineZenocutuzumab Chemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBinimetinibBleomycinBrigatinibCabozantinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEncorafenibEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLazertinibLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabRepotrectinibSelpercatinibSerplulimabSotorasibSugemalimabTelisotuzumab VedotinTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineZenocutuzumab No. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDalteparinDexamethasoneDimetindenFamotidineFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDalteparinDexamethasoneDimetindenFamotidineFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDalteparinDexamethasoneDimetindenFamotidineFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDalteparinDexamethasoneDimetindenFamotidineFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances1234567891011Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationInductionMaintenanceneoadjuvantTherapy intentioncurativecurative or palliativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityColitisConjunctivitisConstipationCOVID-19 infectionDehydrationDiarrheaDizzinessDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Endocrine Side EffectsEsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHemorrhageHepatotoxicityHyperbilirubinemiaHypercholesterolemiaHyperglycemiaHyperkeratosisHyperphosphatemiaHypertensionHyperthyroidismHypertriglyceridemiaHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypophysitisHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNail ChangesNasopharyngitisNauseaNephritisNeuropathyNeurotoxicityNeutropeniaOral MucositisPainParesthesiaPhotosensitivityPneumoniaPneumonitisProteinuriaPruritusPyrexiaQTc Time ExtensionRashRenal FailureSeizuresSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVisual DisturbancesVomiting only studiesPublicationAuthorAlbain KSAntonia SArriagada RArriagada R Belani CPBerghmans TBrahmer JBurotto MCamidge DCamidge DRCappuzzo FCascone TChandra P. BelaniCho BCChoy HC ManegoldC SederholmCurran WDouillard, JYDrilon AEberhardt WE F SmitE QuoixFan CF A ShepherdF BarlesiFelip EF FossellaForde PMGainor JFGandhi LGaron EGeorgoulias VG FrasciGogishvili MGoss GGridelli CGustave Roussy, Villejuif, FranceG V ScagliottiHeigener DFHe JHelbekkmo NHellmann MDHerbst RHeymach JV Hirose TJ-L PujolJD HainsworthJD PatelJoan H. SchillerJohnson MLJP StevensonJänne PAKaira KKawaguchi TKim DKosmidis PKunitoh H Langer CLee SMLeighl NBL G Paz-AresLi BTLu SMaisch BMartinoni A Mazieres JM KarayamaMok TMok T SM ZukinNadal ENakagawa KN HannaO'Brien MPaik PKPark KPark SPassaro APaz-Ares LPeters SP FidiasPirker RP KosmidisPlanchard D Provencio MPujol JLReck MRiely GJRittmeyerR M RuddRossel RSandler, A.Scagliotti et alSchiller JH et al.Schram AMSchuler M Semrau SSequist LVSeto TSezer AShaw AShaw ATSkoulidis FSocincki MSocinski MSocinski MASolomon BSolomon BJSoria JSoria JCStrauss GMSugawara SThomas QDVokes EEWakelee HWang JWest HWinton T WJ TesterWolf JW SchuetteW SchütteWu YWu YLYue DZhong WZZhou CDiseaseAdenokarzinom nichtkleinzelliges Lungenkarzinom, Stadium IIIb/IV oder rezidiviert, ECOG 0-1fortgeschrittenes (Stadium IIIb) oder metastasiertes NSCLC (Patienten älter als 70 Jahre)fortgeschrittenes, metastasiertes oder wiederkehrendes nichtkleinzelliges Adenokarzinom der Lunge, ECOG 0-1Fortgeschrittenes, nichtkleinzelliges Lungenkarzinom, Stadium IIIA und IIIB, Erstlinie, ECOG 0-1fortgeschrittenes, plattenepitheliales, nichtkleinzelliges Lungenkarzinom nach Platinhaltiger Therapie, ECOG 0-1fortgeschrittenes NSCLC, BRAF V600-Mutation, ECOG 0-2fortgeschrittenes NSCLC, nichtresezierbares, Stadium III, ECOG 0-1fortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Erstliniefortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Zweitlinie nach Crizotiniblokal fortgeschrittenes, nichtresektables, nichtkleinzelliges Lungenkarzinom, Stadium III, nach Platin und Radiotherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Erstlinie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Progress unter Crizotinib, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, EGFR Ex19del oder L858R, Progress nach Osimertinib MonotherapieLokal fortgeschrittenes oder metastasiertes Lungenkarzinom, Erstlinie, EGFR Exon 20 Insertionen, ECOG 0-1Maligner Perikarderguss, hämodynamisch relevantMaligner Perikarderguss beim NSCLC, hämodynamisch relevantMeningeosis neoplastica bei NSCLC, EGFR+, nach Vortherapie mit TKI, ECOG 1-3Metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1Metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, keine Mutationen in EGFR, ALK, ROS1 oder RET, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes, nicht operables NSCLC, ALK+, Erstlinie, ECOG 0-2Nichtkleinzelliges Lungen-Ca Stadium IIIb, IV oder RezidivNichtkleinzelliges Lungen-Ca Std. IIIb, IV oder Rezidivnichtkleinzelliges Lungenkarzinom (Adenokarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom (Plattenepithelkarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Adeno-, Stadium IV, Erstlinie, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, metastasiert oder lokal fortgeschritten, Stadium IIIB-IV, ECOG 2-3, über 70 J., nicht fähig für platinbasierte Chemotherapienichtkleinzelliges Lungenkarzinom, Plattenepithel-, Stadium IV, Erstlinie, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, RET+, Stadium IB-IIIA, Erstlinie, adjuvant, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium I, II und III, adjuvant, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium IB, II, IIIA (UICC 8), ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, R0-Resektion, adjuvant, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, adjuvant, nach platinbasierter ChemotherapieNichtkleinzelliges Lungenkarzinom, Stadium IIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom, Stadium IIIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom, Stadium IV, Erstlinie, ECOG 2Nichtkleinzelliges Lungenkarzinom lokal fortgeschritten oder metastasiert, ROS1+, ECOG 0-2nicht resezierbares NSCLC, Stadium I-IIIB, ECOG 0-3Nicht resezierbares NSCLC, Stadium IIIA und IIIB, Erstlinie, ECOG 0-2NSCLC (Adeno-), Stadium IIIb oder IV, EGFR- und ALK-, Erstlinie, ECOG 0-1NSCLC (Adeno-) Stadium III (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIA und IIIB (ohne Pleuraerguss), ECOG 0-1NSCLC (Adeno-) Stadium IIIb (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIb oder IVNSCLC(Adeno-) Std. IIIb und Std. IV, Wenig- oder NichtraucherNSCLC (Adeno-, EGFR-Mutation+) fortgeschrittenNSCLC (Adenokarzinom), mit unbehandelten Hirnmetastasen, EGFR- und ALK-, Erstlinie, ECOG 0-1NSCLC (Adenokarzinom), Stadium IB-IIIA, EGFR mutiert (Ex19del oder L858R), adjuvant, ECOG 0-1NSCLC (Nicht-Plattenepithel) inoperabel Std. IIIb u Std. IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (maligner Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (mit Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb(spraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Stadium IVNSCLC (Nicht-Plattenepithel) Std. IIIb (supraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Std. IVNSCLC, BRAF mutiertNSCLC, ECOG 0-2, perioperativNSCLC, EGFR+, Stadium II-IIIB, ECOG 0-1NSCLC, lokal fortgeschritten oder metastasiert, ECOG 0-1NSCLC, lokal fortgeschritten oder metastasiert, Her2+, nach vorheriger Therapie, ECOG 0-1NSCLC, metastasiert, ECOG 0-2, ErstlinieNSCLC, nicht-plattenepithelial, lokal fortgeschritten oder metastasiert, mind. 1 Vortherapie, c-Met-überexprimierend, EGRF WitldtypNSCLC, perioperativ, ECOG 0-2NSCLC, potenziell resezierbar, Stadium IIIA oder IIIB, ECOG 0-1NSCLC, Stadium IB, II oder IIIA, ALK+, ECOG 0-1NSCLC, Stadium III, nicht operabel, EGFR mutiert (Ex19del oder L858R), nach Radiochemotherapie, ECOG 0-1NSCLC, Stadium IIIa und IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIa und Stadium IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIB oder IV, ALK+, Erstlinie, ECOG 0-2NSCLC, Stadium IIIB oder IV, ALK+, Zweitlinie nach Crizotinib, ECOG 0-2NSCLC, Stadium IIIB oder IV, ECOG 0-1NSCLC, Stadium IIIB oder IV, ELK/EGFR neg., ECOG 0-1NSCLC, Stadium IIIb und IV, Patienten über 70 JahreNSCLC, Stadium II oder IIIA, ECOG 0-1NSCLC, Stadium II und III, nicht resezierbar, Karnofsky > 70NSCLC, Stadium IV, BRAF V600 mutiert, Erstlinie, ECOG 0-2NSCLC, STD. IIIb (mit Pleuraerguss) und Std. IV, älter als 70 Jahre, chemo-naiv, ECOG 0-1NSCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ALK+, Erstlinie, ECOG 0-2NSCLC fortgeschritten oder metastasiert, ALK+, ZweitlinieNSCLC fortgeschritten oder metastasiert, Erstlinie, WHO 0-2NSCLC fortgeschritten oder metastasiert, Ex19del or L858R, ErstlinieNSCLC fortgeschritten oder metastasiert, Ex19del or L858R, Progress nach platinbasierter oder Therapie mit TKINSCLC fortgeschritten oder metastasiert, METex14+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, nach VortherapieNSCLC fortgeschritten oder metastasiert, Progress nach platinbasierter Therapie, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, Zweitlinie nach Progress unter TKI, WHO 0-2NSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten VortherapieNSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten Vortherapie, ECOG 0-2NSCLC im Stadium IIIB/IV, EGFR Mutation, keine Vortherapie für die fortgeschrittene Erkrankung, keine Hirnmetastasen, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Mutation oder MET Amplifikation, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Skipping Mutation, nach vorherigen Therapie, ECOG 0-1NSCLC im Stadium IV, EGFR mutiert (Exon 19 Deletion oder Exon 21 Substitution), ECOG 0-1, keine zerebralen MetastasenNSCLC inoperabel (Stadium IIIa und b), Rezidiv oder Metastasen, Stadium IVNSCLC inoperabel (Std. IIIa u b), Rezidiv oder Metastasen, Std. IVNSCLC lokal fortgeschritten, inoperabel, oder metastasiert, Her2-Mutation, Progress nach platinhaltiger TherapieNSCLC lokal fortgeschritten, nicht operabel oder metastasiert, PD-L1 Expression über 50%, ECOG 0-1NSCLC lokal fortgeschritten, oder metastasiert, EGFR Exon-19-Deletion oder L858R-Mutation, ECOG 0-1NSCLC lokal fortgeschritten oder metastasiert, taxanhaltige Vortherapie, Karnofsky Index 50-100NSCLC metastasiert, nach Rezidiv oder Nichtansprechen einer Vortherapie, ECOG 0-1, ZweitlinieNSCLC metastasiert oder lokal fortgeschritten, RET-Fusion, ECOG 0-2NSCLC metastasiert oder lokal fortgeschritten mit KRAS p.G12C Mutation, Progress nach Immuntherapie und/oder platinbasierter Chemotherapie, ECOG 0-1NSCLC nicht resezierbar oder metastasiert, nach 4 Zyklen platinbasierter Kombinationstherapie ohne ProgressNSCLC nicht resezierbar Stadium IIIb (mit oder ohne Pleuraerguss) und Stadium IVNSCLC Stad. IIIb od IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium III (nicht für Radiatio geeignet) und Stadium IV , Patienten älter als 70 JahreNSCLC Stadium IIIa und Stadium IIIbNSCLC Stadium IIIbNSCLC Stadium IIIb (Pleuraerguss oder met. supraclavic. Lymphknoten) und Stadium IV, Patienten älter als 70 JahreNSCLC Stadium IIIb, IV oder RezidivNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IVNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, < 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malignen Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IVNSCLC Stadium IIIb oder IV, (Plattenepithel-), Zweitlinie nach platinbasierter Therapie, ECOG 0-1NSCLC Stadium IIIb oder IV, Erstlinie für fortgeschrittene Erkrankung, ECOG 0-1NSCLC Stadium IIIB oder IV, Zweit- oder Drittlinie nach Platin, ECOG 0-1NSCLC Stadium IIIb oder IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium IIIb und IVNSCLC Stadium IIIb und IV, exclusive vorrangiger histolog. PlattenepithelkomponenteNSCLC Stadium IIIb und IV, palliativNSCLC Stadium IIIb und IV ohne Eignung zur kurativen TherapieNSCLC Stadium IIIb und Stadium IVNSCLC Stadium IIIb und Stadium IV, EGFR-ExpressionNSCLC Stadium III nicht resezierbarNSCLC Stadium III und IV, palliativ, ZweitlinieNSCLC Stadium IV, PD-L1 Expression > 50%, keine EGFR Mutationen / ALK Translokationen, Erstlinie, ECOG 0-1NSCLC Stadium IV mit Progress unter oder nach Platinum-basierter ErstlinieNSCLC Stadium T2N0, T1N1, T2N1 in adjuvantem Setting nach KomplettresektionNSCLC Stadium V oder IIIb ohne Eignung für multimod. Therapie, Patienten älter als 65 und nicht für Kombinationschemotherapie geeignet)NSCLC Std. I (nur T2N0), Std. II u Std. IIIa nach Komplettresektion, ECOG 0-2, exclusive histolog. brochoalveoläres Ca.NSCLC Std. I, II u III nach KomplettresektionNSCLC Std. IIIa (falls inoperabel), IIIb oder IVNSCLC Std. IIIb (mit Pleuraerguss) u Std. IV, EGFR Mut+(Deletion Exon 19 oder L858R Mut in Exon 21)NSCLC Std. IIIB oder IV, ECOG 0-2, jünger als 75 Jahre, ErstlinieNSCLC Std. IIIb u IV, palliativNSCLC Std. IIIb und IV NSCLC Std. IIIb und IV, Zweit- und Drittlinie bei Patienten ohne Eignung zur weiteren ChemotherapieNSCLC Std. IIIb und Std. IV, EGFR-ExpressionNSCLC Std. IVPlattenepithelkarzinom der Lunge, Stadium IIIB/IIIC/IV, Erstlinie, fortgeschritten oder metastasiert, ECOG 0-1progredientes NSCLC, ALK+, ECOG 0-2RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Stadium IV oder rezidivierend metastasierendes NSCLC, Adeno-, ECOG 0-1 Stadium IV oder rezidivierend metastasierendes NSCLC, EGFR-Mutation oder ALK-Translokation, Progress unter TKIStd. Ib (T2 N0 M0) nach Resektion (Lobektomie oder Pneumektomie); ECOG 0-1Tumore unterschiedlicher Lokalisation, lokal fortgeschritten oder metastasiert, NRG1-Fusion, Zweitlinie, ECOG 0-2vollständig reseziertes, EGFR+ nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, ECOG 0-1OriginAbramson Cancer Center of the University of Pennsylvania, KEYNOTE-021Abteilung für thorakale Onkologie, Krankenhaus Grosshansdorf, Universität Hamburg, DeutschlandAdjuvant Navelbine International Trialist Association (ANITA)American Society of Clinical OncologyBelani CP, University of Pittsburgh Cancer Institute, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, CheckMate 816 trialCancer and Leukemia Group B, Radiation Therapie Group and North Central Cancer Treatment Study GroupsCancer and Leukemia Group B Studie 9431Cancer Center and Research Institute, Magnolia, Tampa, PACIFIC StudieCardiology Unit, Milan, ItalyCentro de Investigacion, Clinica Bradford Hill, Santiago, Chile, IMscin001 trialChina State Key Laboratory of Respiratory Disease and National Clinical Research Centre for Respiratory Disease, Guangzhou, China, NeoADAURA trialChinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, RATIONALE-307 trialChoy H, University of Texas Southwestern, Dallas, TexasChoy H, Vanderbilt University Medical School, Nashville, USACHU Toulouse-Hopital Larrey, Universite Paul Sabatier, Toulouse, France, IFCT-1703 R2D2 TrialC Manegold, Thoraxklinik Heidelberg, DeutschlandCRUK Lung Cancer Centre of Excellence and UCL Cancer Institute, London, UK, IPSOS trialDana-Farber Cancer Institute, Boston, USADepartment of Internal Medicine, Seoul National University Hospital, KoreaDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Internal Medicine and Radiotherapy, West German Cancer Center University, EssenDepartment of Medical Oncology, Baskent University, Adana, Turkey, EMPOWER-Lung 1Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407 InvestigatorsDepartment of Medical Oncology, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, FranceDepartment of Medical Oncology, Shanghai Pulmonary Hospital, China, ASTRUM-004 trialDepartment of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, ESPATUEDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, JapanDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, RTOG 9410Department of Radiotherapy, University of Rostock, Germany, PET-PlanDepartment of Thoracic Oncology, German Center for Lung Research, Germany, IMpower150 Study GroupDepartment of Thoracic Oncology, Grosshnasdorf, Germany, AVAiL trialEastern Cooperative Oncology GroupEuropean Institute of Oncology, IRCCS, Milan, Italy, MARIPOSA-2 trialF A Shepherd, Department of Medical Oncology and Hematology and Radiation Ocology, Toronto, KanadaF Barlesi, Sce Oncologie Multidisciplinaire et Innovations Therapeutiques, Marseille, Frankreich. AVAPERL (MO22089)FLEX Studien TeamGerman Center for Lung Research, LungClinic, Grosshansdorf, Germany, CheckMate 9LAGuangdong Academy of Medical Sciences and General Hospital, China, ADAURA trialGuangdong Lung Cancer Institute, Guangdong General Hospital and Academy of Medical Sciences, Guangzhou, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, ALINA trialGustave Roussy Cancer Campus and Universitiy Paris-Sud, Orsay, FranceHanna N, Indiana University and Hoosier Oncology GroupHelbekkmo N, University of Tromso and Department of Oncology, NorwegenHigh Technology Medical Centre, University Clinic Ltd., Tbilisi, Georgia, EMPOWER-Lung 3Hospital Universitario 12 de Octubre, Universidad Complutense and CiberOnc, Madrid, Spain, CheckMate 9LA studyHospital Universitario 12 de Octubre, Universidad Complutense and CiberOnc, Madrid, Spain, CheckMate 9LA study, KEYNOTE-407Hospital Universitario Puerta de Hierro-Majadahonda, Spain, NADIM II trialInstitut Catala d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain, Atezo-Brain, GECP17/05 trialInstitut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, France, FLAURA2 trialInstitut Jules Bordet, Universite Libre de Bruxelles, BelgiumIntergroupe Francophone de Cancerologie Thoracique, Institut National du Cancer, FrankreichIPASS StudieJ-L Pujol, Montpellier University Hospital, FrankreichJD Patel, R H Lurie Comprehensive Cancer Center, Chicago, USA. PointBreak-StudieJP Stevenson, Abramson Cancer Center, Philadelphia, USAKindai University Faculty of Medicine, Osaka, Japan, RELAYLausanne University Hospital, Lausanne, F. Hoffmann–La Roche, Basel, Switzerland, ALEX TrialLilienbaum R C, Yale Cancer Center, New Haven, USALondon Lung Cancer GroupLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, BostonLUME-Lung 1 Studien Gruppe, LUME-Lung 1 StudieLung Cancer Group - EORTC 08975Lung Clinic, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany, KEYNOTE-024Lungenfachklinik Immenhausen, Immenhausen, Germany, OAK trialLung Unit, Royal Marsden Hospital, London, UK, PEARLS/KEYNOTE-091LUX Lung 3 StudieLUX Lung 8 StudieMaebashi Red Cross Hospital, Department of Respiratory Medicine, Asahicho, Maebashi, JapanMassachusetts General Hospital, Boston, MAMassachusetts General Hospital, Boston, USA, ARROW trialMassachusetts General Hospital, Div. of Hematology -Oncology, USAMassachusetts General Hospital Cancer Center, Boston, USA, CROWN trialMemorial Sloan-Kettering Cancer Center, New York, USAMemorial Sloan Kettering Cancer Center, New YorkMemorial SloanKettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, USA, PHAROS trialMemorial Sloan Kettering Cancer Center, New York, VISION trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-432Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, eNRGy trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, TRIDENT-1 trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, DESTINY-Lung01 trialMILES (The Multicenter Italian Lung Cancer in the Elderly Study)Minnie Pearl Cancer Research NetworkM Karamaya, Department of Internal Medicine, Hamamatsu University, JapanNational Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan, JCOG9811National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States IntergroupNational Hospital Organization, Kinki-Chuo Chest Medical Center, JapanNational Kyushu Cancer Center, Fukuoka, JapanNew York University Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, KEYNOTE-189 InvestigatorsPaz-Ares, Servicio de Oncologia Medica, Seville, Spanien, PARAMOUNT-StudiePaz-Ares, Servicio de Oncologia Medica, Seville, Spanien; PARAMOUNT-StudiePeter MacCallum Cancer Centre, Melbourne, VIC, AustraliaPeter MacCallum Cancer Centre, Melbourne, Victoria, AustralienPirker R, FLEX Studien TeamP Kosmidis, Second Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandPlanchard DPrincess Margaret Cancer Centre, Toronto, ON, Canada, PALOMA-3 studySamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ATTLAS trialSarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, POSEIDON StudySATURN investigators, SATURN StudieScagliotti, Department of Clinical and Biological Sciences, Turin, ItalienScagliotti, Dept. of Clinical and Biological sciences, University of Torino, ItalySecond Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandShanghai Chest Hospital, Department of Oncology, Shanghai, People's Republic of China, RATIONALE-304 trialShanghai Chest Hospital, Department of Oncology, Shanghai, People's Republic of China, RATIONALE 304 trialShanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, LAURA trialShanghai Pulmonary Hospital, School of Medicine Tongji University, Shanghai, China, GEMSTONE-302 trialShanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, PAPILLON trialSidney Kimmel Comprehensive Cancer Center, Baltimore, USA, CheckMate 017Socinski MA, University of Pittsburgh Medical Center, Pittsburgh, USASouthern Italy Cooperative Oncology Group and Interr. Assc. for the Study of Lung Carcinoma, ItalienSouthwest Oncology Group, SWOG 9019Spanish Cancer Group, Groupe Francais de Pneumo-Cancerologie and Assz. Ital. Oncologia Toracica; EURTAC StudieStanford University School of Medicine, Stanford Cancer Institute, Stanford, CA, KEYNOTE-671State Key Laboratory of South China, Chinese University of Hong Kong, ARCHER 1050-StudieSungkyunkwan University School of Medicine,Seoul, South Korea, CHRYSALIS trialTAX 320 Non-Small-Cell Lung Cancer Study Group, USAThe First Department of Internal Medicine, Showa University School of Medicine, Tokyo, JapanThe Greek Oncology Cooperative Group for Lung CancerThe International Adjuvant Lung Cancer Trial Collaborative GroupThe Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupThe Ottawa Hospital Cancer Centre, University of Ottawa, Canada, AURA2The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of ChinaThe Swedish Lung Cancer Study Groupthe TAX 326 Study GroupThe TAX 326 Study GroupThoracic Oncology Program, Swedish Cancer Institute, Seattle, USA, IMpower130Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, CheckMate 227 TrialThoracic Oncology Unit, IFCT, Respiratory Disease Department, Larrey Hospital, CHU, Toulouse, AcSé trialTianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, RATIONALE-315 trialTongji University School of Medicine, Shanghai, People's Republic of China, RATIONALE-304Tongji University School of Medicine, Shanghai, People's Republic of China, RATIONALE 304Translational Research in Oncology-US Network, Los Angeles, USA ; REVEL StudieUniversity Hospital Cologne, Cologne, Germany, GEOMETRY mono-1 trialUniversity Hospital Essen, Essen, Germany, NEOAD trialUniversity of Colorado Cancer Center, Anschutz Cancer Pavilion, ALTA-1LUniversity of Colorado Cancer Center, Aurora, CO, LUMINOSITY TrialUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, CodeBreaK100 trialUniversity of Texas M.D. Anderson Cancer Center, Houston, AEGEAN trialUniversity of Texas M.D. Anderson Cancer Center, Houston, CheckMate 77TUniversity Paris-Sud, Orsay, FranceVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, IMpower010Vanderbilt University, Nashville, Eastern Cooperative Oncology Group (ECOG), USAWeill Cornell Medical College, New York, USAWJ Tester, Alber Einstein Cancer Center, Philadelphia, USAW Schuette, Martha-Maria Stadtkrankenhaus Halle-Doelau, DeutschlandW Schütte, Städtisches Krankenhaus Martha-Maria Halle-Dölau, Universität Halle-WittenbergYale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, KEYNOTE-010Yonsei Cancer Center, Yonsei University College of Medicine, MARIPOSA trialYonsei Cancer Center, Yonsei University College of Medicine, SeoulProtocols in Revision 273 protocols foundAdagrasib 600, Non-Small Cell Lung Cancer (PID2547 V1.0)Afatinib 40, Non-Small Cell Lung Cancer (Squamous) (PID735 V1.0)Afatinib 40, Non-Small Cell Lung Carcinoma, Adeno- (PID197 V1.0)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), First-Line (PID975 V1.0)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), Second Line (PID888 V2.1)Alectinib 600, Non-Small Cell Lung Cancer, adjuvant (PID2614 V1.0)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2525 V1.0)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1208 V1.1)Atezolizumab 1200 / Bevazicumab 15, Maintenance, Non-Small Cell Lung Cancer (PID1209 V1.0)Atezolizumab 1200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1238 V2.0)Atezolizumab 1200 / Pemetrexed 500 / Carboplatin 5 - Atezolizumab 1200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID3070 V1.0)Atezolizumab 1200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Cell Lung Cancer (PID3069 V1.0)Atezolizumab 1200 Maintenance, Non-Small Cell Lung Cancer (PID1272 V1.1)Atezolizumab 1200, Non-Small Cell Lung Cancer, adjuvant (PID2252 V1.0)Atezolizumab 1200, Non-Small Cell Lung Cancer, First-Line (PID1690 V2.0)Atezolizumab 1200, Non-Small Cell Lung Cancer, Second Line (PID886 V1.0)Atezolizumab 1680, Non-Small Cell Lung Cancer, Second Line (PID1663 V1.0)Atezolizumab 1875, single dose subcutaneous (PID3181 V1.1)Atezolizumab 840, Non-Small Cell Lung Cancer, Second Line (PID1662 V1.0)Bleomycin 15, Non-Small Cell Lung Cancer (PID2375 V1.0)Brigatinib 180, Non-Small Cell Lung Cancer, First-Line, Cycle 2+ (PID49 V1.0)Brigatinib 180, Non-Small Cell Lung Cancer, Second Line, Cycle 2+ (PID55 V1.0)Brigatinib 90/180, Non-Small Cell Lung Cancer, First-Line, Cycle 1 (PID48 V1.0)Brigatinib 90/180, Non-Small Cell Lung Cancer, Second Line, Cycle 1 (PID54 V1.0)Cabozantinib 60, Non-Small Cell Lung Cancer (PID556 V2.1)Capmatinib 400, Non-Small Cell Lung Cancer (PID1793 V1.0)Carboplatin 5 / Vinorelbine 25, Non-Small Cell Lung Carcinoma (PID284 V1.1)Cemiplimab 350 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2275 V1.0)Cemiplimab 350 / Paclitaxel 200 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2274 V1.1)Cemiplimab 350 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2271 V1.0)Cemiplimab 350 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2273 V1.1)Cemiplimab 350 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2272 V1.0)Cemiplimab 350, Non-Small Cell Lung Carcinoma (PID1744 V1.0)Cemiplimab 350, Non-Small Cell Lung Cancer, Cycle 5+ (PID2276 V1.0)Ceritinib 450, Non-Small Cell Lung Cancer, First Line (PID1152 V1.1)Ceritinib 450, Non-Small Cell Lung Cancer, Second Line (PID811 V2.0)Cetuximab (400/250) / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 1 (PID190 V2.1)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25 - Cetuximab 250 Maintenance, Non-Small Cell Lung Cancer (PID192 V1.1)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 2-6 (PID191 V2.1)CHRYSALIS - Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, Cycle 1 (PID1912 V1.2)CHRYSALIS - Amivantamab (350/700/1050), Non-Small Cell Lung Cancer, Cycle 1 (PID1908 V1.2)CHRYSALIS - Amivantamab 1050, Non-Small Cell Lung Cancer, Cycle 2+ (PID1909 V1.2)CHRYSALIS - Amivantamab 1400, Non-Small Cell Lung Cancer, Cycle 2+ (PID1913 V1.2)CHRYSALIS - Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 1 (PID3182 V1.0)CHRYSALIS - Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 2+ (PID3184 V1.0)CHRYSALIS - Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 1 (PID3185 V1.0)CHRYSALIS - Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 2+ (PID3187 V1.0)CHRYSALIS - Amivantamab 3520, Non-Small Cell Lung Cancer, Cycle 2+ (PID3183 V1.0)CHRYSALIS - Amivantamab 4640, Non-Small Cell Lung Cancer, Cycle 2+ (PID3186 V1.0)Cisplatin 100 / Etoposide 100, Non-Small Cell Lung Cancer, Adjuvant (PID243 V1.2)Cisplatin 100 / Vinblastine 5 / Radiation, Non-Small Cell Lung Cancer (PID857 V1.1)Cisplatin 20 / Vinorelbine 12.5 / Radiation, Non-Small Cell Lung Cancer (PID669 V1.1)Cisplatin 30, Tumor, Various Organs (PID2371 V1.0)Cisplatin 50 / Etoposide 100 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 4 (PID619 V1.1)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer (PID252 V2.1)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer, Variant 1 (PID858 V1.2)Cisplatin 60 / Etoposide 150, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-3 (PID620 V1.1)Cisplatin 80 / Gemcitabine 1250 / Bevacizumab 7.5, Non-Small Cell Lung Cancer (PID770 V1.1)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), First Line (PID807 V1.2)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line (PID198 V1.1)Crizotinib 250, Non-Small Cell Lung Cancer (METex14+) (PID1984 V1.0)Crizotinib 250, Non-Small Cell Lung Cancer (ROS1+) (PID806 V1.1)Dabrafenib 150 / Trametinib 2, Non-Small Cell Lung Cancer (PID578 V1.0)Dacomitinib 45, Non-Small Cell Lung Cancer (PID1425 V1.0)Docetaxel 35 weekly, Non-Small Cell Lung Cancer (PID166 V1.0)Docetaxel 36 weekly, Non-Small Cell Lung Cancer (PID168 V1.0)Docetaxel 75 / Carboplatin 6, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID154 V1.0)Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma (PID144 V1.1)Docetaxel 75 / Nintedanib 200, Non-Small Cell (Adeno) Lung Carcinoma (PID433 V1.1)Docetaxel 75, Non-Small Cell Lung Carcinoma (PID162 V1.0)Docetaxel 85 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID156 V1.0)Durvalumab 10, Non-Small Cell Lung Carcinoma (PID470 V1.0)Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2495 V1.0)Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2493 V1.0)Durvalumab 1500 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2496 V1.1)Durvalumab 1500 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2494 V1.0)Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2492 V1.1)Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2297 V1.0)Durvalumab 1500, Non-Small Cell Lung Cancer (PID1715 V1.0)Durvalumab 1500, Non-Small Cell Lung Cancer, adjuvant, cycle 5-17 (PID2497 V1.0)Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2291 V1.0)Encorafenib 450 / Binimetinib 45, Non-Small Cell Lung Cancer (PID2764 V1.0)Entrectinib 600, Non-Small Cell Lung Cancer (PID1745 V1.0)Erlotinib 150 / Bevacizumab 15, Non-Small Cell (Adeno) Lung Carcinoma (PID742 V1.0)Erlotinib 150 Maintenance, Non-Small Cell Lung Cancer (PID212 V1.0)Erlotinib 150, Non-Small Cell Lung Cancer (second- and third-line) (PID195 V1.0)Erlotinib 150, Non-Small Cell Lung Cancer, First Line (PID206 V1.0)Gefitinib 250, non-small cell lung carcinoma (PID196 V1.0)Gefitinib 250, Non-Small Cell Lung Cancer, Adjuvant (PID1162 V1.0)Gemcitabine 1000 / Carboplatin 5, Non-Small Cell Lung Cancer (PID132 V1.1)Gemcitabine 1000 / Cisplatin 100, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID146 V1.2)Gemcitabine 1000, Non-Small Cell Lung Cancer (PID172 V1.0)Gemcitabine 1100 / Docetaxel 100, Non-Small Cell Lung Cancer (PID526 V1.0)Gemcitabine 1150, Non-Small Cell Lung Cancer (PID173 V1.0)Gemcitabine 1200 / Carboplatin 5, Non-Small Cell Lung Cancer (PID160 V1.0)Gemcitabine 1200 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID151 V1.2)Gemcitabine 1200, Non-Small Cell Lung Cancer (PID174 V1.0)Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Carcinoma (PID155 V1.0)Gemcitabine 1250 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID159 V1.2)Gemcitabine 1250, Non-Small Cell Lung Cancer (PID171 V1.0)Ifosfamide 2, Non-Small Cell Lung Carcinoma (PID1495 V1.0)Lorlatinib 100, Non-Small Cell Lung Cancer (PID1344 V1.0)Lorlatinib 100, Non-Small Cell Lung Cancer, First Line (PID1673 V1.0)MARIPOSA - Lazertinib 240 / Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, Cycle 1 (PID2835 V1.1)MARIPOSA - Lazertinib 240 / Amivantamab (350/700/1050), Non-Small Cell Lung Cancer, Cycle 1 (PID2836 V1.1)MARIPOSA - Lazertinib 240 / Amivantamab 1050, Non-Small Cell Lung Cancer, Cycle 2+ (PID2838 V1.1)MARIPOSA - Lazertinib 240 / Amivantamab 1400, Non-Small Cell Lung Cancer, Cycle 2+ (PID2837 V1.1)MARIPOSA-2 - Pemetrexed 500 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 5+ (PID3200 V1.0)MARIPOSA-2 - Pemetrexed 500 / Carboplatin 5 / Amivantamab (1600/2240), Non-Small Cell Lung Cancer, Cycle 1 (PID3198 V1.0)MARIPOSA-2 - Pemetrexed 500 / Carboplatin 5 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 2-4 (PID3199 V1.0)Mitomycin 2, Non-Small Cell Lung Cancer (PID2373 V1.0)Mitomycin 8 / Vinorelbine 25, Non-Small Cell Lung Cancer (PID757 V1.0)Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID213 V1.1)Nivolumab - Relatlimab 320, Non-Small Cell Lung Cancer (PID2612 V1.0)Nivolumab 240, Non-Small Cell Lung Cancer, Second Line (PID598 V2.0)Nivolumab 3 / Ipilimumab 1, Non-Small Cell Lung Cancer (PID1231 V1.2)Nivolumab 360 / Carboplatin 5 / Paclitaxel 175, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2642 V1.0)Nivolumab 360 / Carboplatin 5 / Pemetrexed 500, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2643 V1.0)Nivolumab 360 / Cisplatin 75 / Doxetaxel 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2645 V1.0)Nivolumab 360 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2091 V1.0)Nivolumab 360 / Ipilimumab 1 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID3166 V1.0)Nivolumab 360 / Ipilimumab 1 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1670 V1.0)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1669 V1.1)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1676 V1.2)Nivolumab 360 / Ipilimumab 1, Non-Small Cell Lung Cancer, Maintenance (PID1671 V1.0)Nivolumab 360 / Paclitaxel 200 / Carboplatin 5, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-3 (PID2387 V1.0)Nivolumab 360 / paclitaxel 200 / carboplatin 6 / bevacizumab 15 - Nivolumab 360 / bevacizumab 15, non-small cell lung cancer, maintenance (PID2126 V1.0)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15, Non-Small Cell Lung Cancer (PID1929 V1.1)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant (PID2096 V1.0)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2095 V1.1)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2644 V1.0)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 4-9 (PID2388 V1.0)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2646 V1.0)Osimertinib 80 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant (PID2951 V1.0)Osimertinib 80 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2543 V1.0)Osimertinib 80 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2950 V1.0)Osimertinib 80 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2540 V1.0)Osimertinib 80 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2541 V1.0)Osimertinib 80, Non-Small Cell Lung Cancer, Adjuvant (PID1672 V1.0)Osimertinib 80, Non-Small Cell Lung Cancer, Maintenance (PID2697 V1.0)Osimertinib 80, Non-Small Cell Lung Cancer, First Line (PID1100 V1.0)Osimertinib 80, Non-Small Cell Lung Cancer, neoadjuvant (PID2943 V1.0)Osimertinib 80, Non-Small Cell Lung Cancer, Second Line (PID812 V1.0)Paclitaxel 100 / Carboplatin 2, Non-Small Cell Lung Cancer (PID205 V1.1)Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID148 V1.1)Paclitaxel 175 / Cisplatin 50, Non-Small Cell Lung Cancer, Induction, Neoadjuvant, Part A (PID852 V1.2)Paclitaxel 175 / Cisplatin 80, Non-Small Cell Lung Cancer (PID157 V1.2)Paclitaxel 175 / Gemcitabine 1250, Non-Small Cell Lung Cancer (PID158 V1.1)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance , Non-Small Cell Lung Cancer, (Adeno) Part A (PID130 V1.2)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID167 V1.0)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID254 V1.1)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID256 V1.1)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID170 V1.2)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, adjuvant (PID246 V1.1)Paclitaxel 200 / Gemcitabine 1000, Non-Small Cell Lung Cancer (PID169 V1.1)Paclitaxel 200, Non-Small Cell Lung Cancer (PID193 V1.1)Paclitaxel 225 / Carboplatin 6, Non-Small Cell Lung Cancer (PID92 V1.2)Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID253 V1.1)Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID255 V1.2)Paclitaxel 90, Non-Small Cell Lung Cancer (PID194 V1.1)PALOMA-3 - Lazertinib 240 / Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 1 (PID2902 V1.1)PALOMA-3 - Lazertinib 240 / Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 2+ (PID2903 V1.1)PALOMA-3 - Lazertinib 240 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 1 (PID2904 V1.1)PALOMA-3 - Lazertinib 240 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 2+ (PID2905 V1.1)PALOMA-3 - Lazertinib 240 / Amivantamab 3520, Non-Small Cell Lung Cancer, Cycle 2+ (PID3193 V1.0)PALOMA-3 - Lazertinib 240 / Amivantamab 4640, Non-Small Cell Lung Cancer, Cycle 2+ (PID3194 V1.0)PAPILLON - Pemetrexed 500 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 5+ (PID2501 V1.2)PAPILLON - Pemetrexed 500 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 5+ (PID3197 V1.0)PAPILLON - Pemetrexed 500 / Carboplatin 5 / Amivantamab (1600/2240), Non-Small Cell Lung Cancer, Cycle 1 (PID3195 V1.0)PAPILLON - Pemetrexed 500 / Carboplatin 5 / Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, Cycle 1 (PID2498 V1.2)PAPILLON - Pemetrexed 500 / Carboplatin 5 / Amivantamab 1400, Non-Small Cell Lung Cancer, Cycle 2 (PID2499 V1.2)PAPILLON - Pemetrexed 500 / Carboplatin 5 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 3-4 (PID2500 V1.2)PAPILLON - Pemetrexed 500 / Carboplatin 5 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 2-4 (PID3196 V1.0)Pembrolizumab 200 / Cisplatin 75 / Gemcitabine 1000, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-4 (PID2376 V1.0)Pembrolizumab 200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID35 V1.2)Pembrolizumab 200 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID36 V1.1)Pembrolizumab 200 / Paclitaxel 90 / Carboplatin 5 - Pembrolizumab 200, Non-Small Cell Lung Cancer, Cycle 5+ (PID3153 V1.0)Pembrolizumab 200 / Paclitaxel 90 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID3152 V1.0)Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID842 V1.4)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1177 V1.3)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-4 (PID2377 V1.1)Pembrolizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID1170 V1.1)Pembrolizumab 200, non-small cell lung cancer, adjuvant (PID2170 V1.0)Pembrolizumab 200, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2378 V1.0)Pembrolizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID1083 V1.0)Pembrolizumab 200, Non-Small Cell Lung Cancer, First-Line (PID809 V1.0)Pembrolizumab 200, Non-Small Cell Lung Cancer, Second Line (PID808 V2.0)Pembrolizumab 400, Non-Small Cell Lung Cancer, First Line (PID1252 V1.0)Pembrolizumab 400, Non-Small Cell Lung Cancer, Second Line (PID1253 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 1 (PID2529 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 2 (PID2530 V1.0)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 3+ (PID2531 V1.0)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer, (Adeno) Part A (PID250 V1.0)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer (Adeno) Part B (PID251 V1.0)Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (Adeno) (PID178 V1.1)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part A (PID181 V1.1)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part B (PID182 V1.1)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part A (Stevenson) (PID188 V1.0)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (Stevenson) (PID189 V1.0)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 Maintenance, Non-Small Cell Lung Cancer (Adeno) Part A (PID183 V1.1)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 Maintenance, Non-Small Cell Lung Cancer (Adeno) Part B (PID184 V1.0)Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID177 V1.0)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Bevacizumab 7.5 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID187 V1.0)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Pemetrexed 500 / Bevacizumab 7.5 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID186 V1.0)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5, Non-Small Cell Lung Cancer, Part A (PID185 V1.1)Pemetrexed 500 / Cisplatin 75 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID249 V1.0)Pemetrexed 500 / Cisplatin 75 / Radiation, Non-Small Cell Lung Cancer, Part A (PID247 V1.1)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID27 V1.1)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Part A (PID179 V1.3)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), First-Line (PID176 V1.0)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), Second Line (PID175 V1.1)Pemetrexed 500, Non-Small Cell Lung Cancer, Part B, Maintenance (PID180 V1.1)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 2+ (PID1976 V1.0)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 1 (PID1975 V1.0)Pralsetinib 400, Non-Small Cell Lung Cancer (PID1936 V1.0)Ramucirumab 10 / Docetaxel 75, Non-Small Cell Lung Cancer (PID223 V1.2)Ramucirumab 10 / Erlotinib 150, Non-Small Cell Lung Cancer (PID1487 V1.0)Repotrectinib 160, Non-Small Cell Lung Cancer, Cycle 1 (PID554 V2.0)Repotrectinib 160, Non-Small Cell Lung Cancer, Cycle 2+ (PID555 V2.0)Selpercatinib 160, Non-Small Cell Lung Cancer, adjuvant (PID3231 V1.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Serplulimab 4.5 / Nab-Palitaxel 100 / Carboplatin 5 - Serplulimab 4.5, Non-Small Cell Lung Cancer, Maintenance (PID3209 V1.0)Serplulimab 4.5 / Nab-Palitaxel 100 / Carboplatin 5, Non-Small Cell Lung Cancer (PID3208 V1.0)Sotorasib 960, Non-Small Cell Lung Cancer (PID1914 V1.0)Sugemalimab 1200 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID3041 V1.0)Sugemalimab 1200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID3040 V1.0)Sugemalimab 1200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID3042 V1.0)Sugemalimab 1200, Non-Small Cell Lung Cancer, Maintenance (PID3043 V1.0)Telisotuzumab Vedotin 1.9, Non-Small Cell Lung Cancer (PID3024 V1.0)Tepotinib 450, Non-Small Cell Lung Cancer (PID1983 V1.0)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372 V1.0)Tislelizumab 200 / Nab-Paclitaxel 100 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2648 V1.1)Tislelizumab 200 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2647 V1.1)Tislelizumab 200 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-3 (PID2920 V1.1)Tislelizumab 200 / Paclitaxel 175 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-3 (PID2919 V1.1)Tislelizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2635 V1.1)Tislelizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-3 (PID2918 V1.1)Tislelizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID2634 V1.1)Tislelizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-3 (PID2917 V1.1)Tislelizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID2636 V1.1)Tislelizumab 200, Non-Small Cell Lung Cancer (PID2650 V1.1)Tislelizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID2649 V1.1)Tislelizumab 400, Non-Small Cell Lung Cancer (PID3065 V1.0)Tislelizumab 400, Non-Small Cell Lung Cancer, adjuvant, Cycle 4-11 (PID2921 V1.2)Tislelizumab 400, Non-Small Cell Lung Cancer, Maintenance (PID3066 V1.0)Trastuzumab Deruxtecan 5.4, Non-Small Cell Lung Cancer (PID1977 V2.0)Trastuzumab Emtansine 3.6, Non-Small Cell Lung Cancer (PID1982 V1.0)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2293 V1.0)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2294 V1.0)Tremelimumab 75 / Durvalumab 1500 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2290 V1.0)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2295 V1.0)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycles 1-4 (PID2296 V1.1)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 6 (PID2298 V1.0)Tremelimumab 75 / Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 6 (PID2292 V1.0)Vemurafenib 960, Non-Small Cell Lung Cancer (PID1494 V1.0)Vinorelbine 12.5 / Carboplatin 1 / Radiation, Non-Small Cell Lung Cancer (PID668 V1.0)Vinorelbine 15 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer, Part C (PID1169 V1.1)Vinorelbine 15 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer, B (PID262 V1.1)Vinorelbine 20 / Cisplatin 50 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Part B (PID853 V1.1)Vinorelbine 20 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer (PID1193 V1.1)Vinorelbine 20 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer (PID646 V1.1)Vinorelbine 25 / Cisplatin 100, Non-Small Cell Lung Cancer (PID147 V1.1)Vinorelbine 25 / Cisplatin 50, Non-Small Cell Lung Cancer, Adjuvant (PID199 V1.1)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Cancer, A (PID261 V1.2)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Adjuvant (PID34 V1.1)Vinorelbine 25 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma (PID152 V1.0)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Carcinoma (PID150 V1.1)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Cancer, Adjuvant (PID93 V1.2)Vinorelbine 30 / Cisplatin 80, Non-Small Cell Lung Carcinoma (PID153 V1.2)Vinorelbine 30 / Gemcitabine 1200, Non-Small Cell Lung Carcinoma (PID164 V1.2)Vinorelbine 30, Non-Small Cell Lung Cancer (first-line) (PID165 V1.1)Vinorelbine 30, Non-Small Cell Lung Cancer (second-line) (PID163 V1.1)Zenocutuzumab 750, Tumor Biomarker Defined (PID3015 V1.0)
